Nifty
Sensex
:
:
11930.35
40685.50
33.90 (0.28%)
127.01 (0.31%)

Pharmaceuticals & Drugs - Domestic

Rating :
80/99  (View)

BSE: 506820 | NSE: ASTRAZEN

4238.60
9.10 (0.22%)
23-Oct-2020 | 4:11PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  4210.15
  •  4278.85
  •  4205.15
  •  4229.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  12432
  •  526.94
  •  4970.00
  •  1885.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,592.38
  • 152.79
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 10,339.85
  • 0.02%
  • 27.77

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.63%
  • 18.35%
  • FII
  • DII
  • Others
  • 1.98%
  • 2.24%
  • 0.80%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.43
  • 8.09
  • 13.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.52
  • 49.03
  • 21.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.19
  • 68.86
  • 40.73

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 85.85
  • 115.16
  • 113.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.34
  • 22.34
  • 22.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 44.35
  • 60.70
  • 58.12

Quarterly Results

Standalone Figures in Rs. Crores

Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0
0
0
0
0
0
0
0
0
0
0
0
EBITDA
0
0
0
0
0
0
0
0
0
0
0
0
EBIDTM
0%
0%
0%
0%
0%
0%
0%
0%
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
0
0
0
0
0
Tax
0
0
0
0
0
0
0
0
0
0
0
0
PAT
0
0
0
0
0
0
0
0
0
0
0
0
PATM
0%
0%
0%
0%
0%
0%
0%
0%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update


  • AstraZeneca Pharma planning to launch Acalabrutinib capsules ‘Calquence’
    16th Oct 2020, 11:28 AM

    Acalabrutinib100mg capsules Calquence is indicated for the treatment of patients with MCL who have received at least one prior therapy

    Read More
  • Astrazeneca Pharma I - Quarterly Results
    10th Aug 2020, 14:12 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.